BioSpace News Archive

CoNextions® Inc. (www.conextionsmed.com), an innovator in tendon repair, announced that on May 11, 2022, only nineteen days after FDA 510(k) clearance to market the device, the first patient was treated with the CoNextions TR™ Tendon Repair System in a zone 2 flexor tendon in the little finger.

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the quarter ended March 31, 2022, and other recent developments.

Shanghai Junshi Biosciences Co., Ltd announced that the China National Medical Products Administration has approved the supplemental new drug application for toripalimab in combination with paclitaxel and cisplatin in the first-line treatment of patients with unresectable locally advanced/recurrent or distant metastatic esophageal squamous cell carcinoma.

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced first quarter 2022 results and provided a business update.

Blade Therapeutics, Inc., a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced encouraging data from phase 1 and preclinical DDI studies of cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for IPF and other fibrotic diseases.

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”) a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the first quarter of 2022.

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage response pathways today announced that it has acquired Atrin Pharmaceuticals Inc. (“Atrin”) and reported financial results for the three months ended March 31, 2022.

In preclinical animal studies, NVG-291 has demonstrated the potential to promote repair mechanisms in the nervous system, including plasticity, axonal regeneration, and remyelination.

As previously announced, BMS was established to provide technology enabled solutions to the global mining industry by setting up laboratories to address the global backlog in minerals assays.

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced the presentation of additional data for PureTech’s LYT-100 (deupirfenidone) at the American Thoracic Society 2022 International Conference.